{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:03:23Z","timestamp":1793624603021,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018-05766"],"award-info":[{"award-number":["2018-05766"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018-05766"],"award-info":[{"award-number":["2018-05766"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-020-00815-6","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T17:03:02Z","timestamp":1606755782000},"page":"187-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model"],"prefix":"10.1038","volume":"6","author":[{"given":"David W.","family":"Hawman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustaf","family":"Ahl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Sofia","family":"Appelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Meade-White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2652-5695","authenticated-orcid":false,"given":"Vanessa","family":"Monteil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-5611","authenticated-orcid":false,"given":"Stephanie","family":"Devignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9737-337X","authenticated-orcid":false,"given":"Friedemann","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9448-8227","authenticated-orcid":false,"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"S\u00e4llberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-6055","authenticated-orcid":false,"given":"Ali","family":"Mirazimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"815_CR1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.antiviral.2013.07.006","volume":"100","author":"DA Bente","year":"2013","unstructured":"Bente, D. A. et al. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res. 100, 159\u2013189 (2013).","journal-title":"Antiviral Res."},{"key":"815_CR2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa1615162","volume":"377","author":"A Negredo","year":"2017","unstructured":"Negredo, A. et al. Autochthonous Crimean-Congo hemorrhagic fever in Spain. New Engl. J. Med. 377, 154\u2013161 (2017).","journal-title":"New Engl. J. Med."},{"key":"815_CR3","doi-asserted-by":"publisher","unstructured":"Ergonul, O. Crimean-Congo haemorrhagic fever. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/s1473-3099(06)70435-2 (2006).","DOI":"10.1016\/s1473-3099(06)70435-2"},{"key":"815_CR4","unstructured":"Stuart, M. C., Kouimtzi, M. & Hill, S. R. WHO Model Formulary 2008 (World Health Organization, 2008)."},{"key":"815_CR5","first-page":"CD012713","volume":"6","author":"S Johnson","year":"2018","unstructured":"Johnson, S. et al. Ribavirin for treating Crimean Congo haemorrhagic fever. Cochrane Database Syst. Rev. 6, CD012713 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"815_CR6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.antiviral.2018.06.013","volume":"157","author":"DW Hawman","year":"2018","unstructured":"Hawman, D. W. et al. Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. Antiviral Res. 157, 18\u201326 (2018).","journal-title":"Antiviral Res."},{"key":"815_CR7","doi-asserted-by":"crossref","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","volume":"8","author":"L Oestereich","year":"2014","unstructured":"Oestereich, L. et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Neglect. Trop. Dis. 8, e2804 (2014).","journal-title":"PLoS Neglect. Trop. Dis."},{"key":"815_CR8","doi-asserted-by":"crossref","first-page":"11089","DOI":"10.1128\/JVI.01383-10","volume":"84","author":"DA Bente","year":"2010","unstructured":"Bente, D. A. et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J. Virol. 84, 11089\u201311100 (2010).","journal-title":"J. Virol."},{"key":"815_CR9","doi-asserted-by":"crossref","first-page":"e0004210","DOI":"10.1371\/journal.pntd.0004210","volume":"10","author":"JR Spengler","year":"2016","unstructured":"Spengler, J. R., Bergeron, \u00c9. & Rollin, P. E. Seroepidemiological studies of Crimean-Congo hemorrhagic fever virus in domestic and wild animals. PLoS Neglect. Trop. Dis. 10, e0004210 (2016).","journal-title":"PLoS Neglect. Trop. Dis."},{"key":"815_CR10","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3201\/eid2409.171709","volume":"24","author":"O Ergonul","year":"2018","unstructured":"Ergonul, O. et al. Systematic review and meta-analysis of postexposure prophylaxis for Crimean-Congo hemorrhagic fever virus among healthcare workers. Emerg. Infect. Dis. 24, 1642\u20131648 (2018).","journal-title":"Emerg. Infect. Dis."},{"key":"815_CR11","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1016\/j.vaccine.2012.08.003","volume":"30","author":"M Mousavi-Jazi","year":"2012","unstructured":"Mousavi-Jazi, M., Karlberg, H., Papa, A., Christova, I. & Mirazimi, A. Healthy individuals\u2019 immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine. Vaccine 30, 6225\u20136229 (2012).","journal-title":"Vaccine"},{"key":"815_CR12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/00365548.2010.540036","volume":"43","author":"A Papa","year":"2011","unstructured":"Papa, A., Papadimitriou, E. & Christova, I. The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain. Scandi. J. Infect. Dis. 43, 225\u2013229 (2011).","journal-title":"Scandi. J. Infect. Dis."},{"key":"815_CR13","doi-asserted-by":"crossref","first-page":"e91516","DOI":"10.1371\/journal.pone.0091516","volume":"9","author":"KR Buttigieg","year":"2014","unstructured":"Buttigieg, K. R. et al. A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model. PLoS ONE 9, e91516 (2014).","journal-title":"PLoS ONE"},{"key":"815_CR14","doi-asserted-by":"crossref","first-page":"e0006628","DOI":"10.1371\/journal.pntd.0006628","volume":"12","author":"M Zivcec","year":"2018","unstructured":"Zivcec, M., Safronetz, D., Scott, D. P., Robertson, S. & Feldmann, H. Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge. PLoS Neglect. Trop. Dis. 12, e0006628 (2018).","journal-title":"PLoS Neglect. Trop. Dis."},{"key":"815_CR15","doi-asserted-by":"crossref","first-page":"e0005908","DOI":"10.1371\/journal.pntd.0005908","volume":"11","author":"AR Garrison","year":"2017","unstructured":"Garrison, A. R. et al. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. PLoS Neglect. Trop. Dis. 11, e0005908 (2017).","journal-title":"PLoS Neglect. Trop. Dis."},{"key":"815_CR16","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1128\/CVI.05352-11","volume":"18","author":"SM Ghiasi","year":"2011","unstructured":"Ghiasi, S. M., Salmanian, A. H., Chinikar, S. & Zakeri, S. Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus. Clin. Vacc. Immunol. 18, 2031\u20132037 (2011).","journal-title":"Clin. Vacc. Immunol."},{"key":"815_CR17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1089\/vbz.2015.1855","volume":"15","author":"J Kortekaas","year":"2015","unstructured":"Kortekaas, J. et al. Crimean-congo hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but no protection in STAT1 knockout mice. Vector Borne Zoonotic Dis. 15, 759\u2013764 (2015).","journal-title":"Vector Borne Zoonotic Dis."},{"key":"815_CR18","doi-asserted-by":"crossref","first-page":"e0003579","DOI":"10.1371\/journal.pntd.0003579","volume":"9","author":"N Canakoglu","year":"2015","unstructured":"Canakoglu, N. et al. Immunization of knock-out \u03b1\/\u03b2 interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine. PLoS Neglect. Trop. Dis. 9, e0003579 (2015).","journal-title":"PLoS Neglect. Trop. Dis."},{"key":"815_CR19","doi-asserted-by":"crossref","first-page":"e02076-16","DOI":"10.1128\/JVI.02076-16","volume":"91","author":"J Hinkula","year":"2017","unstructured":"Hinkula, J. et al. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and\/or Virus-Like Particles Induces Protection and Survival in Challenged Mice. J. Virol. 91, e02076-16 (2017).","journal-title":"J. Virol."},{"key":"815_CR20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/22221751.2019.1601030","volume":"8","author":"FEM Scholte","year":"2019","unstructured":"Scholte, F. E. M. et al. Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice. Emerg. Microbes Infect. 8, 575\u2013578 (2019).","journal-title":"Emerg. Microbes Infect."},{"key":"815_CR21","volume":"9","author":"SE Rodriguez","year":"2019","unstructured":"Rodriguez, S. E. et al. Vesicular stomatitis virus-based vaccine protects mice against Crimean-Congo hemorrhagic fever. Sci. Rep. 9, 7755 (2019).","journal-title":"Sci. Rep."},{"key":"815_CR22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41564-018-0141-7","volume":"3","author":"E Haddock","year":"2018","unstructured":"Haddock, E. et al. A cynomolgus macaque model for Crimean-Congo haemorrhagic fever. Nat. Microbiol. 3, 556\u2013562 (2018).","journal-title":"Nat. Microbiol."},{"key":"815_CR23","doi-asserted-by":"publisher","unstructured":"Hawman, D. W. et al. Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques. Antiviral Res. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104858 (2020).","DOI":"10.1016\/j.antiviral.2020.104858"},{"key":"815_CR24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","volume":"9","author":"MA Kutzler","year":"2008","unstructured":"Kutzler, M. A. & Weiner, D. B. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9, 776\u2013788 (2008).","journal-title":"Nat. Rev. Genet."},{"key":"815_CR25","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.3362","volume":"19","author":"D Falzarano","year":"2013","unstructured":"Falzarano, D. et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 19, 1313\u20131317 (2013).","journal-title":"Nat. Med."},{"key":"815_CR26","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","volume":"117","author":"E de Wit","year":"2020","unstructured":"de Wit, E. et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc. Natl Acad. Sci. USA 117, 6771\u20136776 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"815_CR27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","volume":"585","author":"BN Williamson","year":"2020","unstructured":"Williamson, B. N. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 585, 273\u2013276 (2020).","journal-title":"Nature"},{"key":"815_CR28","doi-asserted-by":"crossref","first-page":"S794","DOI":"10.1093\/clinids\/11.Supplement_4.S794","volume":"11","author":"R Swanepoel","year":"1989","unstructured":"Swanepoel, R. et al. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev. Infect. Dis. 11, S794\u2013S800 (1989).","journal-title":"Rev. Infect. Dis."},{"key":"815_CR29","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3201\/eid1311.070222","volume":"13","author":"D Duh","year":"2007","unstructured":"Duh, D. et al. Viral load as predictor of Crimean-Congo hemorrhagic fever outcome. Emerg. Infect. Dis. 13, 1769\u20131772 (2007).","journal-title":"Emerg. Infect. Dis."},{"key":"815_CR30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jcv.2015.12.006","volume":"75","author":"I Hasanoglu","year":"2016","unstructured":"Hasanoglu, I. et al. Crucial parameter of the outcome in Crimean Congo hemorrhagic fever: viral load. J. Clin. Virol. 75, 42\u201346 (2016).","journal-title":"J. Clin. Virol."},{"key":"815_CR31","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1469-0691.2006.01445.x","volume":"12","author":"O Ergonul","year":"2006","unstructured":"Ergonul, O., Celikbas, A., Baykam, N., Eren, S. & Dokuzoguz, B. Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited. Clin. Microbiol. Infect. 12, 551\u2013554 (2006).","journal-title":"Clin. Microbiol. Infect."},{"key":"815_CR32","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1093\/ofid\/ofx163.850","volume":"4","author":"F Aksoy","year":"2017","unstructured":"Aksoy, F., Yilmaz, G., Kaya, S., Karahan, S. C. & Koksal, I. The prognostic importance of platelet indices in patients with Crimean-Congo hemorrhagic fever. Open Forum Infect. Dis. 4, S352\u2013S353 (2017).","journal-title":"Open Forum Infect. Dis."},{"key":"815_CR33","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijid.2007.09.010","volume":"12","author":"MA \u00c7evik","year":"2008","unstructured":"\u00c7evik, M. A. et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int. J. Infect. Dis. 12, 374\u2013379 (2008).","journal-title":"Int. J. Infect. Dis."},{"key":"815_CR34","doi-asserted-by":"crossref","first-page":"e0156637","DOI":"10.1371\/journal.pone.0156637","volume":"11","author":"SD Dowall","year":"2016","unstructured":"Dowall, S. D. et al. Protective effects of a modified vaccinia Ankara-based vaccine candidate against Crimean-Congo haemorrhagic fever virus require both cellular and humoral responses. PLoS ONE 11, e0156637 (2016).","journal-title":"PLoS ONE"},{"key":"815_CR35","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1128\/JVI.79.10.6152-6161.2005","volume":"79","author":"A Bertolotti-Ciarlet","year":"2005","unstructured":"Bertolotti-Ciarlet, A. et al. Cellular localization and antigenic characterization of Crimean-Congo hemorrhagic fever virus glycoproteins. J. Virol. 79, 6152\u20136161 (2005).","journal-title":"J. Virol."},{"key":"815_CR36","doi-asserted-by":"crossref","first-page":"eaaw9535","DOI":"10.1126\/sciadv.aaw9535","volume":"5","author":"JW Golden","year":"2019","unstructured":"Golden, J. W. et al. GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection. Sci. Adv. 5, eaaw9535 (2019).","journal-title":"Sci. Adv."},{"key":"815_CR37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.antiviral.2017.08.014","volume":"146","author":"M Zivcec","year":"2017","unstructured":"Zivcec, M. et al. Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus. Antiviral Res. 146, 112\u2013120 (2017).","journal-title":"Antiviral Res."},{"key":"815_CR38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/21645515.2015.1078045","volume":"12","author":"SD Dowall","year":"2016","unstructured":"Dowall, S. D. et al. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease. Hum. Vacc. Immunotherap. 12, 519\u2013527 (2016).","journal-title":"Hum. Vacc. Immunotherap."},{"key":"815_CR39","doi-asserted-by":"publisher","unstructured":"Deyde, V. M., Khristova, M. L., Rollin, P. E., Ksiazek, T. G. & Nichol, S. T. Crimean-Congo hemorrhagic fever virus genomics and global diversity. J. Virol. https:\/\/doi.org\/10.1128\/jvi.00752-06 (2006).","DOI":"10.1128\/jvi.00752-06"},{"key":"815_CR40","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/sj.gt.3302367","volume":"11","author":"F Andr\u00e9","year":"2004","unstructured":"Andr\u00e9, F. & Mir, L. M. DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther. 11, S33\u2013S42 (2004).","journal-title":"Gene Ther."},{"key":"815_CR41","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/mt.2013.119","volume":"21","author":"O Weiland","year":"2013","unstructured":"Weiland, O. et al. Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol. Ther. 21, 1796\u20131805 (2013).","journal-title":"Mol. Ther."},{"key":"815_CR42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","volume":"23","author":"NY Sardesai","year":"2011","unstructured":"Sardesai, N. Y. & Weiner, D. B. Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol. 23, 421\u2013429 (2011).","journal-title":"Curr. Opin. Immunol."},{"key":"815_CR43","doi-asserted-by":"crossref","first-page":"104702","DOI":"10.1016\/j.antiviral.2019.104702","volume":"174","author":"M Zivcec","year":"2020","unstructured":"Zivcec, M., Spiropoulou, C. F. & Spengler, J. R. The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: vaccine efficacy studies. Antiviral Res. 174, 104702 (2020).","journal-title":"Antiviral Res."},{"key":"815_CR44","doi-asserted-by":"publisher","unstructured":"Palacio, N. et al. Early type I IFN blockade improves the efficacy of viral vaccines. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20191220 (2020).","DOI":"10.1084\/jem.20191220"},{"key":"815_CR45","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1016\/j.vaccine.2011.04.043","volume":"29","author":"H Boshra","year":"2011","unstructured":"Boshra, H., Lorenzo, G., Rodriguez, F. & Brun, A. A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR\u2212\/\u2212 mice upon lethal virus challenge. Vaccine 29, 4469\u20134475 (2011).","journal-title":"Vaccine"},{"key":"815_CR46","doi-asserted-by":"crossref","first-page":"8497","DOI":"10.1128\/jvi.71.11.8497-8503.1997","volume":"71","author":"F Rodriguez","year":"1997","unstructured":"Rodriguez, F., Zhang, J. & Whitton, J. L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71, 8497 (1997).","journal-title":"J. Virol."},{"key":"815_CR47","doi-asserted-by":"publisher","unstructured":"Hawman, D. W. et al. A Crimean-Congo hemorrhagic fever mouse model recapitulating human convalescence. J. Virol. https:\/\/doi.org\/10.1128\/JVI.00554-19 (2019).","DOI":"10.1128\/JVI.00554-19"},{"key":"815_CR48","doi-asserted-by":"crossref","unstructured":"Sasseville, V. G., Hotchkiss, C. E., Levesque, P. C. & Mankowski, J. L. in Nonhuman Primates in Biomedical Research 2nd edn (eds Abee, C. R., Mansfield, K., Tardif, S. & Morris, T.) 357\u2013384 (Academic Press, 2012).","DOI":"10.1016\/B978-0-12-381366-4.00007-9"},{"key":"815_CR49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5625\/lar.2016.32.1.46","volume":"32","author":"K Choi","year":"2016","unstructured":"Choi, K. et al. Reference values of hematology, biochemistry, and blood type in cynomolgus monkeys from Cambodia origin. Lab. Animal Res. 32, 46\u201355 (2016).","journal-title":"Lab. Animal Res."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-00815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-00815-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-00815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:54:38Z","timestamp":1733957678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-00815-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["815"],"URL":"https:\/\/doi.org\/10.1038\/s41564-020-00815-6","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S. is a founder and chairman of the board of Svenska Vaccinfabriken Produktion AB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}